NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for bivalent recombinant LP2086 (rLP2086), the company’s vaccine candidate for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B in 10 to 25 year olds.
Pfizer Announces Submission of Biologics License Application to the FDA for Investigational Meningococcal B Vaccine | Pfizer Pharmaceutical News and Media | Pfizer: the world's largest research-based pharmaceutical company
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.